Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology)

N/A

Report date: 2025/05/15 20:00:08

Base Information

Drug NameAnti-CD19+/BCMA CAR-T cells (Hrain Biotechnology)
Drug Alias NameAnti-CD19/BCMA bispecific CAR T cell therapyAnti-CD19 anti-BCMA bispecific chimeric antigen receptor T cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD19 +[4] 
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsPOEMS Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesHrain Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHrain Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsPOEMS Syndrome

Other Information

ATC CodeN/A
Related LinksN/A